Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose.
Amro Maher StinoNaresh BummaRachel SmithLong DavalosJeff AllenJing Christine YeMatthew PiankoErica CampagnaroCassandra FierroAbdelrahman AwadBen MurdockMaciej PietrzakGerard LoszanskiDavid M KlineYvonne EfeberaBakri ElsheikhPublished in: European journal of neurology (2023)
Lenalidomide in Anti-MAG Neuropathy: Phase 1b Study, ClinicalTrials.gov Identifier: NCT03701711, https://clinicaltrials.gov/ct2/show/NCT03701711. First submitted October 10, 2018. First patient enrolled in January 2019.